Treatment with nivolumab/ipilimumab combination did not result in tumor growth inhibition, yet an inflammatory response was observed demonstrated by the upregulation of pro-inflammatory cytokines and a shift in TILs composition in favor of CD8+ T cells (85) (Figure 2A). This evidence concerns the gene CD8A and neoplasm.